Mark Cuban calls Yusimry's availability on MCCPDC 'a game changer'

In a statement to MobiHealthNews, the cofounder of Mark Cuban Cost Plus Drug Company expressed excitement over the deal to offer the discounted Humira alternative.
By Jessica Hagen
07:18 pm
Share

Mark Cuban Cost Plus Drug Company (MCCPDC) announced that it's working with Coherus Biosciences to sell Yusimry, a biosimilar version of the top-selling drug Humira, at a discounted price. 

Yusimry is used to treat several diseases, such as rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis, hidradenitis suppurativa, Crohn’s disease and plaque psoriasis.

The medication will be available through MCCPDC starting July 2023, and cost $569.27, plus dispensing and shipping fees. It will be the first biologic product offered by the discount drug supplier. 

In February, MCCPDC announced a new program via Twitter that aims to create an independent pharmacists' network where members would be provided a "Team Cuban Benefits Card." MCCPDC said in a statement that Yusimry would be included in the benefits program through participating pharmacies. 

"Coherus's Yusimry is a game changer. Having an alternative to Humira that is affordable will improve the lives of patients everywhere. Costplusdrugs.com is truly excited to make Yusimry available to everyone in a transparent manner," Mark Cuban told MobiHealthNews in an email. 

THE LARGER TREND

Since MCCPDC's launch in 2022, it's developed numerous partnerships and collaborations.

In April, the company announced a collaboration with Seattle-based Zócalo Health, a virtual healthcare service for Latino patients, to expand Zócalo members' access to lower-cost prescription medication. 

That same month, Fierce Healthcare reported MCCPDC teamed up with RevSpring, a health payment solutions company, to run a program with U.S. pharmacies to make drugs more affordable for consumers. 

MCCPDC has also established partnerships with California-based EmsanaRx and Tennessee-based RxPreferred Benefits. It has announced collaborations with diabetes and chronic disease management company Diathrive Health and cancer care support company OncoPower.

MCCPDC was also integrated into Rightway Health's platform, allowing the pharmacy benefit manager's members access to MCCPDC.

Last year, the company also announced its first health plan partnership with Capital Blue Cross, noting Capital's members could use their insurance cards at MCCPDC directly as of the start of 2023.

Share